Search Result

Results for "

atherosclerotic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acetyl-CoA Carboxylase (2) Acyltransferase (4) Adrenergic Receptor (8) Akt (2) AMPK (2) Angiotensin Receptor (1) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (1) Apoptosis (15) ATP-binding cassette (ABC) transporters (1) Autophagy (5) Bacterial (5) Bcl-2 Family (1) Biochemical Assay Reagents (3) Bombesin Receptor (2) Caspase (3) COX (3) Cytochrome P450 (1) Endogenous Metabolite (13) Epoxide Hydrolase (1) ERK (3) FAAH (1) Fatty Acid Synthase (FASN) (3) Ferroptosis (2) Fluorescent Dye (1) Formyl Peptide Receptor (FPR) (1) Free Fatty Acid Receptor (2) Glutathione Peroxidase (3) GSK-3 (2) Heme Oxygenase (HO) (1) HMG-CoA Reductase (HMGCR) (6) HSP (2) Imidazoline Receptor (8) Interleukin Related (8) Isotope-Labeled Compounds (11) JNK (2) LDLR (11) Liposome (4) LPL Receptor (1) LXR (3) Mitophagy (5) MMP (6) mTOR (2) NF-κB (6) NO Synthase (5) NOD-like Receptor (NLR) (2) P2Y Receptor (1) p38 MAPK (2) Parasite (2) PCSK9 (4) PDGFR (1) PGE synthase (2) PI3K (2) Potassium Channel (4) PPAR (6) Prostaglandin Receptor (1) Pyroptosis (3) Reactive Oxygen Species (ROS) (6) Reference Standards (8) Scavenger Receptor Class B type I (SR-BI） (1) Ser/Thr Protease (1) Sirtuin (2) Small Interfering RNA (siRNA) (2) TGF-beta/Smad (2) TNF Receptor (2) Toll-like Receptor (TLR) (3)
By Research Areas:	Cancer (19) Cardiovascular Disease (66) Endocrinology (1) Infection (7) Inflammation/Immunology (23) Metabolic Disease (37) Neurological Disease (19)
Oligonucleotides:	CpG ODNs (2) siRNA drugs (2) Antisense Oligonucleotides (1) siRNAs (2)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P2310A

Defensin HNP-1 human TFA	Bacterial Parasite	Infection Cardiovascular Disease
Defensin HNP-1 human TFA is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human TFA exhibits broad antimicrobial and anti-leishmanial activities .

HY-119770

HDL376 SDZ-HDL 376	Scavenger Receptor Class B type I (SR-BI）	Cardiovascular Disease
HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC₅₀ = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease .

HY-B0218

Orlistat Maximum Cited Publications 24 Publications Verification Tetrahydrolipstatin; Ro-18-0647	Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity ^[1]. Anti-atherosclerotic effect .

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

HY-132591A

Inclisiran sodium 4 Publications Verification ALN-PCSsc sodium	PCSK9 Small Interfering RNA (siRNA) Pyroptosis PPAR NOD-like Receptor (NLR) Caspase Interleukin Related	Cardiovascular Disease Metabolic Disease
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-N4247

Kuwanon G	Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .

HY-172181

NSC380324	P2Y Receptor	Cardiovascular Disease
NSC380324 is a P2Y₁₂ receptor antagonist, possessing antiplatelet activity, and can be utilized in research on atherosclerotic cardiovascular diseases .

HY-P2310

Defensin HNP-1 human	Bacterial Parasite	Infection Cardiovascular Disease
Defensin HNP-1 human is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human exhibits broad antimicrobial and anti-leishmanial activities .

HY-173591

T0080	Formyl Peptide Receptor (FPR) Apoptosis Reactive Oxygen Species (ROS) Interleukin Related	Cardiovascular Disease
T0080 is a FPR-1 antagonist. T0080 reduces the cell apoptosis, inhibits ROS production and pro-inflammatory cytokines (TNF-α and IL-1β) from plaque macrophages, which attenuates atherosclerotic progression in ApoE ^−/− mice .

HY-W709553

Glyceryl Triformate Triglyceride	Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology
Glyceryl Triformate (Triglyceride) is the major form of storage and transport of fatty acids within cells and in the plasma. Glyceryl Triformate forms lipoproteins with cholesterol ester, and participates in the blood circulation. Glyceryl Triformate can lead to hypertriglyceridemia (HTG), which increases the risk of atherosclerotic cardiovascular disease (ASCVD) and pancreatitis .

HY-117006

E1231 1 Publications Verification 1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one	Sirtuin	Cardiovascular Disease
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC₅₀=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (K_D=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE ^-/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases .

HY-W010697

Cholesteryl linoleate	Endogenous Metabolite	Metabolic Disease
Cholesteryl linoleate is shown to be the major cholesteryl ester contained in LDL and atherosclerotic lesions.

HY-N1553

Pseudolaric acid D	Others	Cardiovascular Disease Inflammation/Immunology
Pseudolaric acid D is a compound with oral activity that can be isolated from Pseudolarix kaempferi Gorden. Pseudolaric acid D can significantly improve lipid metabolism, reduce atherosclerotic lesion area, and alleviate atherosclerotic changes in vascular wall. Pseudolaric acid D significantly inhibits the inflammatory reaction .

HY-173322

Lp(a)-IN-8	LPL Receptor
Lp(a)-IN-8 (compound 15) is an Lp(a) inhibitor. Lp(a) is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD) .

HY-116150

Xymedon	Others	Cardiovascular Disease
Xymedon is a pyrimidine derivative with anti-atherosclerotic effects. Xymedon reducts plasma cholesterol levels and cholesterol esterification in blood vascular cells .

HY-159001

ZCDD083	Biochemical Assay Reagents	Others
ZCDD083 can be used as a positron emission tomography (PET) tracer for atherosclerotic plaques imagination, when labeled with ¹⁸F isotope .

HY-W010697S

Cholesteryl linoleate-d11	Isotope-Labeled Compounds Endogenous Metabolite	Metabolic Disease
Cholesteryl linoleate-d₁₁ is deuterium labeled Cholesteryl linoleate. Cholesteryl linoleate is shown to be the major cholesteryl ester contained in LDL and atherosclerotic lesions .

HY-W013812S

Ethyl linoleate-13C18 Linoleic Acid-¹³C₁₈ ethyl ester; Mandenol-¹³C₁₈	Isotope-Labeled Compounds	Cardiovascular Disease
Ethyl linoleate- ¹³C₁₈ is the ¹³C labeled Ethyl linoleate. Ethyl linoleate inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-U00054

LDL-IN-3	LDLR	Cardiovascular Disease Metabolic Disease
LDL-IN-3 is an anti-atherosclerotic compound extracted from patent WO/2005/039596A1, example C25 and patent US 6133467, example 3.

HY-W013812R

Ethyl linoleate (Standard) Linoleic Acid ethyl ester (Standard); Mandenol (Standard)	Reference Standards Others	Cardiovascular Disease
Ethyl linoleate (Standard) is the analytical standard of Ethyl linoleate. This product is intended for research and analytical applications. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-130587

Sultosilic acid piperazine salt Piperazine sultosylate; A-585	Others	Metabolic Disease
Sultosilic acid piperazine salt (Piperazine sultosylate; A-585) is a lipid-lowering agent. Sultosilic acid piperazine salt modifies the blood lipids levels, reduces platelet adhesiveness without promoting peroxisomal activity of hepatocytes or producing other adverse side-effects .

HY-158825

Cepadacursen sodium CIVI007 sodium	PCSK9	Metabolic Disease
Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia treatment and the prevention of atherosclerotic cardiovascular disease (ASCVD).

HY-E70559

Prostaglandin D synthase	PGE synthase	Cardiovascular Disease Cancer
Prostaglandin D synthase is a biomarker for meningioma cells and coronary artery disease. Lipocalin-type Prostaglandin D synthase (L-PGDS) is present in the atherosclerotic plaque of the human coronary artery and can be detectable in human serum .

HY-W013812S3

Ethyl linoleate-d11 Linoleic Acid ethyl ester-d₁₁; Mandeno-d₁₁	Isotope-Labeled Compounds Others	Cardiovascular Disease
Ethyl linoleate-d₁₁ (Linoleic Acid ethyl ester-d₁₁) is deuterium labeled Ethyl linoleate. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-113870

6-NBDG	Fluorescent Dye	Others
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .

HY-W013812S1

Ethyl linoleate-d5 Linoleic Acid ethyl ester-d5; Ethyl linoleate, pure-d5; Mandenol-d₅	Isotope-Labeled Compounds Others	Cardiovascular Disease
Ethyl linoleate-d₅ (Linoleic Acid ethyl ester-d₅) is deuterium labeled Ethyl linoleate. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators . .

HY-113420

11-Dehydro-thromboxane B2	Endogenous Metabolite	Metabolic Disease
11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-107637

ONO-4817	MMP	Cardiovascular Disease
ONO-4817 is a potent inhibitor of matrix metalloproteinase (MMP). Inhibition of matrix metalloproteinases (MMPs) is expected to suppress atherosclerotic neointimal proliferation and thus limits atheromatous plaque progression. ONO-4817 suppresses the development of aortic intimal hyperplasia in experimental hyperlipidemic rabbit .

HY-W041171S

3-Chloro-L-tyrosine-13C6	Endogenous Metabolite	Others
3-Chloro-L-tyrosine- ¹³C₆ is the ¹³C labeled 3-Chloro-L-tyrosine . 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima .

HY-B0218S

Orlistat-d3 Tetrahydrolipstatin-d₃; Ro-18-0647-d₃	Isotope-Labeled Compounds Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity ^[2].?Anti-atherosclerotic?effect .

HY-W013812S2

Ethyl linoleate-d2 Linoleic Acid ethyl ester-d₂; Mandenol-d₂	Isotope-Labeled Compounds	Cardiovascular Disease
Ethyl linoleate-d₂ (Linoleic Acid ethyl ester-d₂; Mandenol-d₂) is the deuterium labeled Ethyl linoleate (HY-W013812). Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-172708A

DSPE-PEG3400-PP1	Liposome	Neurological Disease
DSPE-PEG3400-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG3400-PP1 can be used for drug delivery .

HY-B0218R

Orlistat (Standard) Maximum Cited Publications 24 Publications Verification Tetrahydrolipstatin (Standard); Ro-18-0647 (Standard)	Reference Standards Fatty Acid Synthase (FASN) Apoptosis	Metabolic Disease Cancer
Orlistat (Standard) is the analytical standard of Orlistat. This product is intended for research and analytical applications. Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity . Anti-atherosclerotic effect .

HY-172709

DSPE-PEG5000-PP1	Liposome	Neurological Disease
DSPE-PEG5000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG5000-PP1 can be used for drug delivery .

HY-172708

DSPE-PEG2000-PP1	Liposome	Neurological Disease
DSPE-PEG2000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG2000-PP1 can be used for drug delivery .

HY-172707

DSPE-PEG1000-PP1	Liposome	Neurological Disease
DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .

HY-119265

LDL-IN-4	Acyltransferase	Metabolic Disease
LDL-IN-4 (Compound 2) inhibits human acyl-CoA:cholesterol acyltransferase-1 and -2 activities. LDL-IN-4 inhibits copper-mediated low density lipoprotein (LDL) oxidation, with an IC₅₀ of 3 μM. LDL-IN-4 has anti-atherosclerotic biological activity .

HY-12403A

Talfirastide acetate 10+ Cited Publications TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-123016

9(S)-HODE cholesteryl ester	Endogenous Metabolite	Cardiovascular Disease
9(S)-HODE cholesteryl ester is originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid peroxidation.2 9(S)-HODE cholesteryl ester can be used as a standard for analysis of chiral HODE cholesteryl esters.

HY-125394

9(R)-HODE cholesteryl ester	Endogenous Metabolite	Cardiovascular Disease
9(R)-HODE cholesteryl ester is originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid peroxidation.2 9(R)-HODE cholesteryl ester can be used as a standard for analysis of chiral HODE cholesteryl esters.

HY-W747575

(+/-)13-HODE cholesteryl ester	Endogenous Metabolite	Metabolic Disease
(±)13-HODE cholesteryl ester is originally extracted from atherosclerotic lesions1 and shown to be produced by Cu2+-catalyzed oxidation of LDL. Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 13-HODE cholesteryl ester.

HY-118486

LDL-IN-1	Acyltransferase	Metabolic Disease
LDL-IN-1 (Compound 1) is an antioxidant, and is active against copper mediated LDL oxidation (IC₅₀ = 52 μM). LDL-IN-1 is also an Acyl-CoA:cholesterol acyltransferase-1 and -2 (ACAT-1/2) inhibitor, with IC₅₀s of 60 μM. LDL-IN-1 can be used for anti-atherosclerotic research .

HY-146245

ODN 1826 4 Publications Verification CpG 1826	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-146245C

ODN 1826 sodium 4 Publications Verification CpG 1826 sodium	Toll-like Receptor (TLR) Apoptosis NO Synthase	Cardiovascular Disease Inflammation/Immunology Cancer
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

HY-W424839

Probucol dithiobisphenol DTBP	Heme Oxygenase (HO)	Cardiovascular Disease
Probucol dithiobisphenol (DTBP) is the derivative of Probucol (HY-B0388). Probucol dithiobisphenol induces the production of heme oxygenase 1 (HO-1), and exhibits antioxidant activity. Probucol dithiobisphenol inhibits atherosclerotic lesions in Apoe ^−/− mice aorta, promotes re-endothelialization of aorta and inhibits restenosis in rabbit arterial injury models. Probucol dithiobisphenol is orally active .

HY-122266

Orcein	Biochemical Assay Reagents	Metabolic Disease
Orcein is an irreversible stain that specifically targets elastic fibers and can interact hydrophobically with the protein components in elastic fibers. Orcein makes elastic fibers in tissues appear purple or purple-red. Orcein can be used for morphological studies of Drosophila polytene chromosomes and for qualitative and quantitative analysis of elastic fibers, collagen fibers and other components in atherosclerotic plaques .

HY-123016A

(±)9-HODE cholesteryl ester	Endogenous Metabolite	Metabolic Disease
(±)9-HODE cholesteryl ester is originally extracted from atherosclerotic lesions1 and shown to be produced by Cu2+-catalyzed oxidation of LDL.2 Later studies determined that 15-LO from rabbit reticulocytes and human monocytes were able to metabolize cholesteryl linoleate, a major component of LDL, to 9-HODE cholesteryl ester.

HY-173230

ABCA1 inducer 2	ATP-binding cassette (ABC) transporters LXR	Cardiovascular Disease
ABCA1 inducer 2 is a non-lipotropic ABCA1 inducer. ABCA1 inducer 2 upregulates the expression of ABCA1 by targeting the LXR pathway. ABCA1 inducer 2 can reduce ox-LDL-induced lipid accumulation and thus inhibit foam cell formation. ABCA1 inducer 2 has anti-atherosclerotic potential .

HY-14928

Lobeglitazone	PPAR ERK JNK TGF-beta/Smad NO Synthase COX NF-κB Interleukin Related	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone is the orally active agonist for PPAR with EC₅₀ of 137.4 nM and 546.3 nM for PPARγ and PPARα. Lobeglitazone is the inhibitor for ERK/JNK/Smad/NF-κB signaling pathway. Lobeglitazone exhibits anti-inflammatory, anti-diabetic, anti-fibrotic and anti-atherosclerotic properties .

HY-155773

VU534	FAAH Epoxide Hydrolase	Cardiovascular Disease
VU534 is a NAPE-PLD activator, with an EC₅₀ of 0.30 μM. VU534 is dual inhibitors of FAAH and sEH (IC₅₀ of 1.2 μM). VU534 increases efferocytosis in a NAPE-PLD dependent manner. VU534 has the potential for cardiometabolic diseases study ^[1].

Cat. No.	Product Name	Type

HY-113870

6-NBDG	Fluorescent Dyes/Probes
6-NBDG is a fluorescent glucose analogue, it can be used for fluorescence imaging and monitoring glucose transport and uptake. 6-NBDG can be used as a fluorescent probe for detecting macrophage-rich atherosclerotic plaques .

HY-122266

Orcein

Dyes

Orcein is an irreversible stain that specifically targets elastic fibers and can interact hydrophobically with the protein components in elastic fibers. Orcein makes elastic fibers in tissues appear purple or purple-red. Orcein can be used for morphological studies of Drosophila polytene chromosomes and for qualitative and quantitative analysis of elastic fibers, collagen fibers and other components in atherosclerotic plaques .

Cat. No.	Product Name	Type

HY-130502

5β,6β-epoxycholestanol Cholesterol 5beta,6beta-epoxide	Drug Delivery
5β,6β-epoxycholestanol is an oxidative metabolite of cholesterol formed by free-radical and non-radical oxidation of cholesterol at the 5,6 double bond. Induces lactate dehydrogenase (LDH) release and apoptosis in macrophage-differentiated U937 cells. Cholesterol 5beta,6beta-epoxide has been found in human fatty streaks and advanced atherosclerotic lesions, but not in normal aortic tissue .

HY-172708A

DSPE-PEG3400-PP1	Drug Delivery
DSPE-PEG3400-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG3400-PP1 can be used for drug delivery .

HY-172709

DSPE-PEG5000-PP1	Drug Delivery
DSPE-PEG5000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG5000-PP1 can be used for drug delivery .

HY-172708

DSPE-PEG2000-PP1	Drug Delivery
DSPE-PEG2000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG2000-PP1 can be used for drug delivery .

HY-172707

DSPE-PEG1000-PP1	Drug Delivery
DSPE-PEG1000-PP1 is a PEG compound which composed of DSPE and a PP1 peptide. PP1 peptide targets the inflammatory atherosclerotic plaque. DSPE-PEG1000-PP1 can be used for drug delivery .

Cat. No.	Product Name	Target	Research Area

HY-P2310A

Defensin HNP-1 human TFA	Bacterial Parasite	Infection Cardiovascular Disease
Defensin HNP-1 human TFA is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human TFA exhibits broad antimicrobial and anti-leishmanial activities .

HY-P10918

F11R peptide TFA	Peptides	Inflammation/Immunology
F11R peptide TFA is a F11 receptor molecule. F11R peptide TFA inhibits anti-F11R antibody-induced platelet aggregation, and inhibits the adhesion of platelets to cytokine (TNFα and INF-γ)-inflammed endothelial cells. F11R peptide TFA can be used for research of atherosclerotic plaques and associated thrombotic disease .

HY-12403A

Talfirastide acetate 10+ Cited Publications TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-P2310

Defensin HNP-1 human	Bacterial Parasite	Infection Cardiovascular Disease
Defensin HNP-1 human is a Human neutrophil peptides (HNPs), involved in endothelial cell dysfunction at the time of early atherosclerotic development. Defensin HNP-1 human exhibits broad antimicrobial and anti-leishmanial activities .

Cat. No.	Product Name	Target	Research Area

HY-P9930

Evolocumab 2 Publications Verification AMG 145	NF-κB Ser/Thr Protease Toll-like Receptor (TLR)	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N4247

Kuwanon G	Infection Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Phenols Polyphenols Plants Moraceae Disease Research Fields Morus alba Linn.	Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR
Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .

HY-W010697

Cholesteryl linoleate	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Cholesteryl linoleate is shown to be the major cholesteryl ester contained in LDL and atherosclerotic lesions.

HY-113420

11-Dehydro-thromboxane B2	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-12403A

Talfirastide acetate Maximum Cited Publications 12 Publications Verification TXA127 acetate; Angiotensin (1-7) acetate; Ang-(1-7) acetate	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields Endocrinology	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium .

HY-N0403

2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside	Structural Classification Polygonaceae Reynoutria japonica Houtt. Source classification Phenols Polyphenols Plants	Apoptosis
2,3,4',5-Tetrahydroxystilbene 2-O-β-D-glucoside (TSG) is an active product that can be extracted from Polygonum multiflorum Thunb. TSG has anti-inflammatory, antioxidative, anti-atherosclerotic, anti-apoptotic, and free radical scavenging activities, TSG is also indicated to facilitate long-term potentiation and learning and memory in both normal and pathological conditions .

HY-113342

7-Ketocholesterol 2 Publications Verification	Triterpenes Structural Classification Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite p38 MAPK
7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .

HY-N1553

Pseudolaric acid D	Structural Classification Pinaceae Terpenoids Source classification Diterpenoids Pseudolarix amabilis (J. Nelson) Rehder Plants	Others
Pseudolaric acid D is a compound with oral activity that can be isolated from Pseudolarix kaempferi Gorden. Pseudolaric acid D can significantly improve lipid metabolism, reduce atherosclerotic lesion area, and alleviate atherosclerotic changes in vascular wall. Pseudolaric acid D significantly inhibits the inflammatory reaction .

HY-W013812R

Ethyl linoleate (Standard) Linoleic Acid ethyl ester (Standard); Mandenol (Standard)	Structural Classification Natural Products Gramineae Source classification Setaria italica Plants	Reference Standards Others
Ethyl linoleate (Standard) is the analytical standard of Ethyl linoleate. This product is intended for research and analytical applications. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-N13869

Asperlin	Structural Classification Natural Products Microorganisms Source classification	Antibiotic Bacterial Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family NO Synthase COX TNF Receptor Interleukin Related
Asperlin is an orally active marine-derived antibiotic with antifungal, anticancer, anti-inflammatory and anti-atherosclerotic activities. Asperlin induces apoptosis. Asperlin increases reactive oxygen species (ROS)- and DNA damage-associated G2/M phase arrest and ATM phosphorylation. Asperlin is effective in preventing HFD-induced obesity and modulating gut microbiota .

HY-113342R

7-Ketocholesterol (Standard)	Triterpenes Structural Classification Terpenoids Source classification Endogenous metabolite	Endogenous Metabolite p38 MAPK
7-Ketocholesterol (Standard) is the analytical standard of 7-Ketocholesterol. This product is intended for research and analytical applications. 7-Ketocholesterol is an oxidation product of cholesterol, widely present in atherosclerotic plaques, and has a stronger atherogenic effect than cholesterol. 7-Ketocholesterol can inhibit the rate-limiting enzymes involved in bile acid and cholesterol synthesis, such as cholesterol 7α-hydroxylase and HMG-CoA reductase. 7-Ketocholesterol exhibits pro-inflammatory effects both in vivo and in vitro and can induce cell apoptosis (apoptosis) .

HY-N2673

5-Heptadecylresorcinol 5-n-Heptadecylresorcinol; AR-C17	Structural Classification Gramineae Source classification Secale cereale Phenols Polyphenols Plants	Sirtuin
5-Heptadecylresorcinol (AR-C17), a phenolic lipid component, is also an orally active mitochondrial protector. 5-Heptadecylresorcinol improves mitochondrial function via sirtuin3 signaling pathway, thus alleviates endothelial cell damage and apoptosis. 5-Heptadecylresorcinol induces sirtuin3-mediated autophagy. 5-Heptadecylresorcinol reduces the atherosclerotic plaques in the aortic root region of mice heart. 5-Heptadecylresorcinol can be used for research of atherosclerosis prevention and obesity .

HY-N4247R

Kuwanon G (Standard)	Structural Classification Flavonoids Flavones Source classification Phenols Polyphenols Plants Moraceae Morus alba Linn.	Reference Standards Bombesin Receptor Bacterial Apoptosis Reactive Oxygen Species (ROS) PI3K Akt GSK-3 MMP mTOR NF-κB LXR
Kuwanon G (Standard) is the analytical standard of Kuwanon G (HY-N4247). This product is intended for research and analytical applications. Kuwanon G is a flavonoid compound and an antagonist of the bombesin receptor. Kuwanon G has multiple activities such as bactericidal, anti-tumor, anti-inflammatory, antioxidant, anti-atherosclerotic, and neuroprotective effects. Kuwanon G exhibits strong antibacterial activity against oral pathogens, especially cariogenic bacteria and periodontal pathogens. Kuwanon G can induce apoptosis and inhibit proliferation, migration, and invasion of tumor cells. Kuwanon G can be used in the research of diseases such as gastric cancer and atherosclerosis .

HY-N1934

Dihydroberberine	Cardiovascular Disease Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields	Potassium Channel HSP
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-129440

N-(p-Coumaroyl) Serotonin	Structural Classification Classification of Application Fields Carthamus tinctorius L. Source classification Phenols Polyphenols Plants Compositae Inflammation/Immunology Disease Research Fields	PDGFR ERK Caspase
N-(p-Coumaroyl) Serotonin is a selective inhibitor of PDGFRβ, ERK1/2 and caspase-8 with antioxidant, anti-atherosclerotic and anti-inflammatory properties. N-(p-Coumaroyl) Serotonin inhibits glioblastoma cells (U251MG, T98G) with IC₅₀ of 48-81 μM, while the IC₅₀ for normal fibroblasts is 181-197 μM. N-(p-Coumaroyl) Serotonin inhibits PDGF signaling (reducing receptor phosphorylation), blocks Ca ²⁺ influx, and induces apoptosis (activating caspase-8). N-(p-Coumaroyl) Serotonin can improve atherosclerosis and aortic wall enlargement, and can also be used in the study of glioblastoma .

HY-N0853

Alisol A 4 Publications Verification	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Classification of Application Fields Terpenoids Source classification Other Diseases Alismataceae Plants Disease Research Fields	AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related
Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity .

HY-N1934R

Dihydroberberine (Standard)	Alkaloids Structural Classification other families Source classification Plants Isoquinoline Alkaloids	Reference Standards Potassium Channel HSP
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-N0853R

Alisol A (Standard)	Triterpenes Structural Classification Alisma plantago-aquatica Linn. Terpenoids Source classification Alismataceae Plants	Reference Standards AMPK Acetyl-CoA Carboxylase PPAR MMP Interleukin Related
Alisol A (Standard) is the analytical standard of Alisol A (HY-N0853). This product is intended for research and analytical applications. Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity .

Cat. No.	Product Name	Chemical Structure

HY-W041171S

3-Chloro-L-tyrosine-13C6
3-Chloro-L-tyrosine- ¹³C₆ is the ¹³C labeled 3-Chloro-L-tyrosine . 3-Chloro-L-tyrosine is a specific marker of myeloperoxidase-catalyzed oxidation, and is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima .

HY-W010697S

Cholesteryl linoleate-d11
Cholesteryl linoleate-d₁₁ is deuterium labeled Cholesteryl linoleate. Cholesteryl linoleate is shown to be the major cholesteryl ester contained in LDL and atherosclerotic lesions .

HY-W013812S

Ethyl linoleate-13C18
Ethyl linoleate- ¹³C₁₈ is the ¹³C labeled Ethyl linoleate. Ethyl linoleate inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-W013812S3

Ethyl linoleate-d11
Ethyl linoleate-d₁₁ (Linoleic Acid ethyl ester-d₁₁) is deuterium labeled Ethyl linoleate. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-W013812S1

Ethyl linoleate-d5
Ethyl linoleate-d₅ (Linoleic Acid ethyl ester-d₅) is deuterium labeled Ethyl linoleate. Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators . .

HY-B0218S

Orlistat-d3
Orlistat-d3 is a deuterated labeled Orlistat . Orlistat (Tetrahydrolipstatin) is a well-known irreversible inhibitor of pancreatic and gastric lipases. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity ^[2].?Anti-atherosclerotic?effect .

HY-W013812S2

Ethyl linoleate-d2
Ethyl linoleate-d₂ (Linoleic Acid ethyl ester-d₂; Mandenol-d₂) is the deuterium labeled Ethyl linoleate (HY-W013812). Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators .

HY-113420S2

11-Dehydro-thromboxane B2-13C5
11-Dehydro-thromboxane B2- ¹³C₅ is ¹³C labeled 11-Dehydro-thromboxane B2 (HY-113420). 11-Dehydro-thromboxane B2 is a platelet hemagglutinin. Thromboxane inhibition was assessed by urinary excretion levels of 11-Dehydro-thromboxane B2. 11-Dehydro-thromboxane B2 can be used in the study of atherosclerotic thrombosis .

HY-B0374S1

Moxonidine-d7

Moxonidine-d₇ is deuterated labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374AS

Moxonidine-13C,d3 hydrochloride

Moxonidine- ¹³C,d₃ hydrochloride is ¹³C and deuterated labeled Moxonidine hydrochloride (HY-B0374A). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374S2

Moxonidine-d3

Moxonidine-d₃ (BDF5895-d₃) is deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

HY-B0374S

Moxonidine-d4

Moxonidine-d₄ (BDF5895-d₄) is the deuterium labeled Moxonidine (HY-B0374). Moxonidine (BDF5895) is an orally active imidazoline type 1 receptor (I₁-R) agonist. Moxonidine activates imidazoline I₁ receptors and α₂ adrenoceptors, affecting oxidized low-density lipoprotein uptake. Moxonidine reduces atherosclerotic lesions and lowers blood pressure. Moxonidine can be used in the study of hypertension, heart failure, and atherosclerosis .

Cat. No.	Product Name		Classification

HY-132591A

Inclisiran sodium 4 Publications Verification ALN-PCSsc sodium		siRNAs siRNA drugs
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-146245

ODN 1826 4 Publications Verification CpG 1826		CpG ODNs
ODN 1826 is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 induces NO and iNOS production and enhances Apoptosis. ODN 1826 enhances immune surveillance. ODN 1826 increases aortic atherosclerotic plaque size. ODN 1826 has antitumor activity against lung cancer, glioma and melanoma .

HY-146245C

ODN 1826 sodium 4 Publications Verification CpG 1826 sodium		CpG ODNs
ODN 1826 sodium is a class B CpG ODN (oligodeoxynucleotide) and TLR9 agonist. ODN 1826 sodium induces NO and iNOS production and enhances Apoptosis. ODN 1826 sodium enhances immune surveillance. ODN 1826 sodium increases aortic atherosclerotic plaque size. ODN 1826 sodium has antitumor activity against lung cancer, glioma and melanoma .

HY-132591

Inclisiran 4 Publications Verification ALN-PCSsc		siRNAs siRNA drugs
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-158825

Cepadacursen sodium CIVI007 sodium		Antisense Oligonucleotides
Cepadacursen sodium is a liver-targeting antisense oligonucleotide (ASO), inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) protein synthesis. Cepadacursen sodium can be used for hypercholesterolemia treatment and the prevention of atherosclerotic cardiovascular disease (ASCVD).

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

atherosclerotic

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products